Evidence map›Paper›PMID 39474536›Full record

ArticleCase reports in oncology

Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report.

Yutaka Fujiwara, Katsuhiro Masago, Reiko Matsuzawa, Teppei Yamaguchi, Naohiro Watanabe, Junichi Shimizu, Eiichi Sasaki, Yoshitsugu Horio

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yutaka FujiwaraDepartment of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan.
Katsuhiro MasagoDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
Reiko MatsuzawaDepartment of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan.
Teppei YamaguchiDepartment of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan.
Naohiro WatanabeDepartment of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan.
Junichi ShimizuDepartment of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan.
Eiichi SasakiDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
Yoshitsugu HorioDepartment of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) are at increased risk of central nervous system (CNS) metastasis at initial diagnosis and throughout treatment. In a phase 3 trial, lorlatinib, a third-generation ALK tyrosine kinase inhibitor, significantly improved progression-free survival. In further analysis, lorlatinib revealed superior intracranial efficacy and prolonged time to intracranial progression compared with crizotinib. Case Presentation: Herein, we report a case of ALK-positive NSCLC with leptomeningeal metastasis that was successfully treated with lorlatinib after progression to brigatinib and alectinib. This case demonstrates the potential of lorlatinib in managing leptomeningeal metastasis in ALK-positive NSCLC. Conclusion: The case suggests a paradigm shift in therapeutic approaches for CNS metastasis, including brain and leptomeningeal metastases.

Indexed as

Anaplastic lymphoma kinase fusionLeptomeningeal metastasisLorlatinibNon-small cell lung cancer

Identifiers

PMID39474536
PMCPMC11521437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.